Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant.

Antiviral research - 1 Jun 2011

Delogu Ilenia, Pastorino Boris, Baronti Cécile, Nougairède Antoine, Bonnet Emilie, de Lamballerie Xavier

Abstract excerpt

Arbidol (ARB) is an antiviral drug originally licensed in Russia for use against influenza and other respiratory viral infections. Although a broad-spectrum antiviral activity has been reported for this drug, there is until now no data regarding its effects against alphavirus infection. Here, the in vitro antiviral effect of ARB on Chikungunya virus (CHIKV) replication was investigated and this compound was found...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alphavirus Infections
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cell Line

Share to Chikungunya Fever

Share to Chikungunya virus

Share to Drug Resistance, Viral

Share to Indoles

Share to Virus Replication

Source

Identifiers

PMID: 21440006
DOI: 10.1016/j.antiviral.2011.03.182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant.PMID 21440006Read ↗

Chikungunya virus drug discovery: still a long way to go?Semantic proximity Read ↗

Popular Influenza Antiviral Drugs: Mechanisms, Efficacy, and ResistanceSemantic proximity Read ↗

Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral.Semantic proximity Read ↗

Efficacy and Safety Evaluation of Arbidol in Patients with COVID-19Semantic proximity Read ↗

Identification of [1,2,3]Triazolo[4,5-<i>d</i>]pyrimidin-7(6<i>H</i>)-ones as Novel Inhibitors of Chikungunya Virus ReplicationSemantic proximity Read ↗

Development of a high-throughput antiviral assay for screening inhibitors of chikungunya virus and generation of drug-resistant mutations in cultured cells.Semantic proximity Read ↗

Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201.Semantic proximity Read ↗

Isolation and characterization of an arildone-resistant poliovirus 2 mutant with an altered capsid protein VP1.Semantic proximity Read ↗

PA subunit of RNA polymerase as a promising target for anti-influenza virus agents.Semantic proximity Read ↗

The broad-spectrum antiviral drug arbidol inhibits foot-and-mouth disease virus genome replicationSemantic proximity Read ↗

Chikungunya Virus Infection of Cell Lines: Analysis of the East, Central and South African LineageSemantic proximity Read ↗

Mutation in Enterovirus 71 Capsid Protein VP1 Confers Resistance to the Inhibitory Effects of Pyridyl ImidazolidinoneSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.